Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus intravenous and intraperitoneal paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (phase III)
jRCTs051180199Phase 3Active, not recruiting
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tegafur and paclitaxel in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC). Primary endpoint: Overall survival. Started Feb 2020; status: active, not recruiting.
02
Drugs
tegafurpaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs051180199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180199.